#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in JAMA Oncology.
Click to read this study in The Lancet Oncology.
Click to read this study in JAMA Oncology.
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients ...
Click to read this study in JAMA Network Open.
1. Total pathological complete response was not significantly different between trastuzumab and HD201. 2. HD201 has a comparable safety profile ...
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained. 2. Even if pertuzumab were free, ...
1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from reference biologic products 2. The design ...
1. Patients with refractory HER2-mutant non-small cell lung cancer (NSCLC) show clinical response to trastuzumab deruxtecan. 2. Safety profiles were ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.